×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RLMD – relmada therapeutics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RLMD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
01:34 pm
rlmd
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
11/19
09:14 am
rlmd
Relmada Therapeutics to Present at Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Relmada Therapeutics to Present at Jefferies London Healthcare Conference [Yahoo! Finance]
11/19
09:00 am
rlmd
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Medium
Report
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
11/14
07:39 am
rlmd
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease [Yahoo! Finance]
Low
Report
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease [Yahoo! Finance]
11/14
07:30 am
rlmd
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
Low
Report
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
11/8
02:48 am
rlmd
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]
11/7
04:32 pm
rlmd
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/7
04:23 pm
rlmd
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/7/2024
04:10 pm
RLMD
relmada therapeutics, inc.
MISS
Report
3.5%
relmada therapeutics, inc.
8/7/2024
04:05 pm
RLMD
relmada therapeutics, inc.
BEAT
Report
-29.0%
relmada therapeutics, inc.
5/8/2024
04:05 pm
RLMD
relmada therapeutics, inc.
BEAT
Report
-0.8%
relmada therapeutics, inc.
3/19/2024
04:15 pm
RLMD
relmada therapeutics, inc.
BEAT
Report
-17.4%
relmada therapeutics, inc.
Date
Time
Symbol
Headline
Impact
11/14
09:41 am
rlmd
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: Deep Track Capital, LP
Neutral
Report
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: Deep Track Capital, LP
11/7
04:07 pm
rlmd
Form 10-Q RELMADA THERAPEUTICS, For: Sep 30
Medium
Report
Form 10-Q RELMADA THERAPEUTICS, For: Sep 30
10/23
04:27 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: Oct 22 Filed by: CASAMENTO CHARLES J
Low
Report
Form 4 RELMADA THERAPEUTICS, For: Oct 22 Filed by: CASAMENTO CHARLES J
9/13
06:05 am
rlmd
Form EFFECT RELMADA THERAPEUTICS,
Medium
Report
Form EFFECT RELMADA THERAPEUTICS,
9/11
05:47 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: Shenouda Maged
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: Shenouda Maged
9/11
05:47 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: CASAMENTO CHARLES J
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: CASAMENTO CHARLES J
9/11
05:47 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: TRAVERSA SERGIO
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: TRAVERSA SERGIO
9/11
05:46 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: Kelly Paul Edward
Medium
Report
Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: Kelly Paul Edward
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/14
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
134.0%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%
12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%
3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%
3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%
10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%
3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%
5/16 Form D RELMADA THERAPEUTICS, 8.2%
3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%
5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%
TOP News Decliners
10/17
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
-18.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%
10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%
7/10 Form D/A RELMADA THERAPEUTICS, -10.5%
1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%
3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%
3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%
10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%
5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%
4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: